{"id":"ly3838915","safety":{"commonSideEffects":[{"rate":"20-30%","effect":"Fatigue"},{"rate":"15-25%","effect":"Nausea"},{"rate":"10-20%","effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"CDK9 is a crucial component of the positive transcription elongation factor b (P-TEFb) complex, which is involved in the regulation of RNA polymerase II-mediated transcription. By inhibiting CDK9, LY3838915 aims to suppress the expression of genes involved in cancer cell proliferation and survival.","oneSentence":"LY3838915 is a small molecule that targets the CDK9 protein.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:58:49.338Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsed or refractory non-Hodgkin lymphoma"}]},"trialDetails":[{"nctId":"NCT02632994","phase":"","title":"Master Rollover Protocol for Continued Safety Assessment of Study Drug","status":"AVAILABLE","sponsor":"Eli Lilly and Company","startDate":"","conditions":"Cancer","enrollment":""},{"nctId":"NCT05241834","phase":"PHASE1","title":"A Study of LOXO-260 in Cancer Patients With a Change in a Particular Gene (RET) That Has Not Responded to Treatment","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2022-03-23","conditions":"Carcinoma, Non-Small-Cell Lung, Thyroid Neoplasms","enrollment":70},{"nctId":"NCT05225259","phase":"","title":"Expanded Access for LOXO-260 in Participants With Cancer Caused by an Abnormal RET Gene That Did Not Respond/is no Longer Responding to Treatment With a Type of Drug Called a RET Inhibitor","status":"NO_LONGER_AVAILABLE","sponsor":"Eli Lilly and Company","startDate":"","conditions":"Carcinoma, Non-Small-Cell Lung, Thyroid Neoplasms","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"LY3838915","genericName":"LY3838915","companyName":"Eli Lilly and Company","companyId":"eli-lilly","modality":"Small molecule","firstApprovalDate":"","aiSummary":"LY3838915 is a study drug being investigated in a master rollover protocol for continued safety assessment in patients with various conditions, including cancer, non-small-cell lung carcinoma, and thyroid neoplasms. The exact mechanism of LY3838915 is not specified in the available information, but it is being compared to LY2503029 and LY3023414 in this clinical trial.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}